Saturday, August 31, 2013

Should You "Friend" the Facebook IPO?

The media hype is starting: Rumors abound that Facebook will soon announce plans to sell shares to the public. Whispers set a $100 billion price tag as a possible valuation for the social media giant; it would be the largest internet initial public offering (IPO) ever, and the fourth largest IPO of any type.

Interest is intense; after all nearly 800 million users spend hours daily on the site, trading pictures, political banter, recipes, reconnecting with old friends and searching for new ones. No website has captured the imagination and time of so many across the globe.

Pundits say we can only imagine the advertising, data mining, and related revenue that could be generated. The value of networks, it's said, rises exponentially with their size. Facebook is a unique property and represents a unique opportunity for investors. But, does it merit your investment dollars?

Bottom Line

Steer clear of this IPO. Profitable investing requires focus on the financial metrics. Tallies of clicks, unique users, and time spent on a website is of little value and can't be analyzed except by the revenues and profits generated. The rumored price tag puts the shares in bubble land, where the downside risks far outweigh any upside hopes.

Growth is sure to slow. Converting from private to public will produce headwinds. Historically, these types of companies have disappointed, while the recent track record of social media IPOs has been anything but inspiring.

Avoid the Bubble Land Valuation

The proposed Facebook IPO pricing would value the company at up to $100 billion. Unfortunately, when analyzed in the context of its recent financial results, that just doesn't make sense.

Facebook is said to have generated $4 billion in revenues last year, with profits of $1.5 billion. That means the price to earnings ratio is nearly 70; absent growth you'd be better off with a ten year Treasury bond, which would yield you $2 billion for every $100 billion invested.

Sin! ce growth is expected, compare it to other Internet leaders. Google is valued at nearly $200 billion, but last year generated nearly 10 times the revenues and 6 times the profit. So, if Facebook is really going to be the next Google (GOOG), its value is closer to $33 billion, one third of projections.

Yahoo, too, is another pure Internet play. It generated more revenue than Facebook in the last 12 months but its market capitalization is just one fifth of Facebook's hoped for $100 billion. Investors will pay more for faster growth. Analysts expect 20% per annum growth out of Google, which gives Google a "PEG ratio" (its price to earnings ratio divided by its growth rate) of about one, given Google's recent price to earnings ratio of 20. But, if you apply a PEG of one to Facebook, it would have to grow earnings nearly 70% annually to justify a 70 price to earnings ratio.

Is that possible? No question, Facebook has done that in the past. But, no company does that for long. That would imply a doubling of the company annually.

A $100 billion valuation incorporates lots of eye popping results, and then some. Your maximum upside is dwarfed by your potential losses should the rosy forecasts not materialize.

Recent Growth Rates Unsustainable; Future Growth May Slow

In recent years, Facebook has doubled in size annually, and that's inspiring the aspirational pricing. As you get bigger, the law of large numbers sets in and percentage rates of growth decline; the low hanging fruit has already been picked. The next 800 million users will be harder to find than the first 800 million users. In effect, to capture another 800 million users Facebook needs to find a region as big as Europe and they all have to sign up for Facebook, no matter their age or even whether they have a computer!

Success breeds competition; Google+, Google's answer to Facebook, has already signed up 90 million users, and has the heft and experience to go head to head with Facebook. Just keeping the 800 ! million c! urrent users will be a challenge, as Twitter, LinkedIn, Google, and undoubtedly guys inventing in garages right now conspire to vie for current Facebookers.

Increasing size invites more scrutiny; if Facebook is viewed as a monopoly regulators here and abroad may want to break it up, like an AT&T (T) or a Microsoft (MSFT). A phalanx of Facebook lawyers trying to navigate the shoals of increased regulation won't help growth.

To maintain growth rates, successful penetration overseas, especially China, is critical. But, that's not easy. Remember Google had to withdraw from China.

Facebook now has $3.5 billion cash on its balance sheet. It aspires to raise $10 billion in its IPO. That could leave it with over $13 billion cash on its balance sheet. Investors don't pay 70 times earnings for cash earning nothing. There'll be tremendous pressure to deploy, but will it be deployed wisely?

Distractions of Being a Public Company May Impede

The most important Facebook metric today is the number of users, estimated at 800 million. After the IPO the stock price may well be the critical number. Will this cause founder Mark Zuckerberg and his team to take their eyes off the ball?

Zuckerberg prides himself on building a business for the long term. Once you're public, unfortunately, Wall Street wants quarterly results. Many lament that this makes long term growth plans far more difficult.

Indeed, Zuckerberg may not want to go public, but probably feels compelled to. It's widely believed that Facebook now has over 500 stockholders, which requires it to file its financial statements publicly before May. This will cause Facebook to lose a major advantage of being private, keeping confidential its financial results.

Once an IPO makes Zuckerberg and his employees billionaires and millionaires, will complacency set in? Will Facebook continue to be the scrappy, hungry startup that laid the groundwork for the success?

Bottom line, don't extrapolate mindlessly into t! he future! Facebook's historical growth rates.

Internet IPOs' Historical Performance Scary

History is littered with internet IPOs that crashed and burned. The examples are legion: The Globe.com was one of the first social media sites; despite soaring 6 fold following its IPO in the late 1990s, it soon was dismembered. But, only after a founder was filmed partying with his girlfriend model, saying "Got the girl. Got the money. Now I'm ready to live a disgusting, frivolous life."

Yahoo joined the S&P as its first Internet name in December 2000, trading well over 100; 11 years later it's down nearly 90%, never having paid a dividend.

Early Facebook investors were mocked because MySpace ruled the roost back in 2005. MySpace was then sold to News Corp for $580 million and by June of 2006 it surpassed Google as the most frequented US website. But, the tides of fortune shift; last year MySpace was ranked 138th by web traffic and was unloaded for a mere $35 million.

It's true that Google has been successful, rising nearly six fold from its IPO debut. But, it came public at a more reasonable $23 billion market cap, just a fourth of the hoped for Facebook number.

This history should serve as a warning to would be buyers of Facebook's IPO.

Recent Performance of Social Media IPOs Disappointing

The social media darling of 2011, Groupon, despite initially soaring, has come back to earth, and now trades nearly exactly at its IPO price. Social media gamer Zynga, which has built its business around Facebook's platform, also remains at its IPO price.

Investors should heed these recent results before piling into the Facebook IPO. Indeed, this may be the reason some are suggesting that Facebook's IPO price will come in as much as 25% lower than implied by the initially touted $100 billion market cap. No one at Facebook wants its shareholders to have a Zynga or Groupon experience.

In sum, enjoy the Facebook pages, but don't friend the shares; the downside risk far! outweigh! s the upside hopes.

Friday, August 30, 2013

Top Heal Care Companies For 2014

View

NHAI tax-free bond issue is a good investment opportunity for investors expecting to earn returns better than bank fixed deposits and complete safety of their capital, given its tax-free stature and NHAI� creditworthiness.

The issue is highly recommended, especially, for investors who fall in the 20 and 30% tax-bracket, as it would technically increase their yield much higher due to their tax-free nature. The interest rate of 8.2%-8.3% p.a., offered by this issue is higher than the rates offered by the commercial banks on their fixed deposits if we take into consideration the tax benefit on this. It will earn an investor a spread of 200-300 basis points at a zero incremental risk vis-a-vis other investment options in similar category.

Considering the tax benefit in this bond, currently no other debt product in the market is offering such high interest rate with this high safety net. Moreover, at this juncture the interest rates is soon expected to see a downward slope and this issue allows you to lock-on to these high rates for 10 or 15 years, which is quite a good return for a safe debt instrument.

Top Heal Care Companies For 2014: Amerigon Incorporated(ARGN)

Amerigon Incorporated engages in the design, development, and marketing of electronic components and systems based on thermoelectric device technologies for heating and cooling applications. The company principally offers the Climate Control Seat, a variable temperature seat climate control system that provides temperature comfort to automobile passengers. It also provides automotive seat comfort systems, including automotive seat heaters, climate comfort systems for automotive seats, automotive steering wheel heater systems, and integrated electronic components; and specialized automotive cable systems comprising ready-made wire harnesses and related wiring products. The company sells its products to automobile and light truck original equipment manufacturers or their tier one seating suppliers, as well as to the automotive aftermarket, ski lifts, and sports stadiums primarily in the United States, Germany, Korea, China, Japan, Mexico, Canada, the United Kingdom, and Taiw an. Amerigon Incorporated was founded in 1991 and is headquartered in Northville, Michigan.

Top Heal Care Companies For 2014: Kingold Jewelry Inc.(KGJI)

Kingold Jewelry, Inc. engages in the design, manufacture, and sale of gold jewelry and Chinese ornaments in the People?s Republic of China. It provides a range of gold products, including gold necklaces, rings, earrings, bracelets, pendants, and gold bars. The company sells its products under the Kingold brand name to distributors, retailers, and wholesalers covering 19 provinces in China. Kingold Jewelry, Inc. was founded in 2002 and is based in Wuhan, the People?s Republic of China.

Top 5 Financial Stocks To Watch Right Now: Mesa Uranium Corp (MSA.V)

Mesa Exploration Corp., an exploration stage company, engages in the identification, acquisition, and exploration of mineral properties in the United States. It primarily explores for uranium, lithium, and potash mineral properties. The company holds interests in various mineral properties located in Utah and Arizona. It primarily holds interests in the Bounty potash project that consist of 104 square miles of potash leases and exploration permits located in the Great Salt Lake Desert of western Utah. The company was formerly known as Mesa Uranium Corp. and changed its name to Mesa Exploration Corp. in March 2011. Mesa Exploration Corp. is headquartered in Vancouver, Canada.

Top Heal Care Companies For 2014: AirMedia Group Inc(AMCN)

AirMedia Group Inc., through its subsidiaries, operates digital media network for air travel advertising in China. The company operates a network of digital frames and digital TV screens that display advertisements in airports and airplanes. It also displays advertisements on interior or exterior walls of gate bridges in airports, which include billboard and painted advertisements. In addition, the company displays non-advertising content, such as weather, sports, and comedy clips; and TV programs, including documentaries and hidden camera type reality shows from other third-party content providers. Further, it holds concession rights to operate various traditional advertising media comprising billboards, light boxes, and other media platforms out of the air travel sector. As of March 1, 2011, the company operated approximately 3,424 digital frames in 34 airports; 2,144 digital TV screens in 37 airports; 588 light boxes and billboards in 3 airports; 240 billboard advertise ments; and 46 painted advertisements on the gate bridges located in 7 airports. AirMedia Group Inc. was founded in 2005 and is headquartered in Beijing, the People's Republic of China.

Top Heal Care Companies For 2014: Sinobest Technology Hldgs Ltd. (T80.SI)

Sinobest Technology Holdings Ltd., an investment holding company, provides computer and network system integration, building integration, application software development, and technical services in the People's Republic of China. It offers e-archive management, social security allied office, public security joint approving, e-document exchange center, e-regulation and policy, e-conference, e-financial management, and performance assessment solutions for the government; and government internal Website portal, short message service, office automation, email, decision making support, information service management, and service management information solutions for public servants. The company also offers online applying and approving, and enterprise information service solutions for businesses; community service, e-Medicare, online applying and approving, public information service, e-identity verification, and hotline service solutions for public; and application support, ser vice application, and network infrastructure solutions. It primarily serves government bureaus and departments, and state-owned enterprises in the sectors of telecommunication service, power supply, railway and transportation, immigration and customs, public security, labor and social insurance, universities, land and resources, taxation and finance, and food and drugs, as well as privately-owned enterprises. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China Sinobest Technology Holdings Ltd. is a subsidiary of Profit Saver International Limited.

Top Heal Care Companies For 2014: Golden Arrow Resources Corporat (GRG.V)

Golden Arrow Resources Corporation, a junior mineral exploration company, engages in advancing, identifying, and acquiring precious and base metal projects in Argentina. It has interests in approximately 40 exploration properties. The company�s projects include Potrerillos gold-silver project, Pescado gold project, and Mogote copper-gold-silver porphyry/epithermal project in San Juan Province; Chinchillas silver project located in Jujuy Province; Purulla copper-moly project in Catamarca Province; Don Bosco Copper-Gold Project, Caballos copper-gold project, and Varitas Polymetallic project in La Rioja Province; and Costa Property, Las Bayas property, and Victoria property in Chubut Province. Golden Arrow Resources Corporation is based in Vancouver, Canada.

Thursday, August 29, 2013

Deere Posts Mixed Retail Sales in May - Analyst Blog

Top Growth Stocks To Own Right Now

Shares of agricultural, forestry and construction equipment manufacturer Deere & Company (DE) fell 1.2% after it announced mixed retail sales for May.

Sales Performance

In the agriculture and turf segment, Deere's U.S. and Canada utility tractor sales growth were flat in May, compared to the industry wide sales growth of 4%. Deere's inventory was reported to be lower than the industry wide inventory of utility tractors, which stood at 49% of the previous 12 months sales.

However, sales of row crop tractor outperformed the industry growth rate of 27% during the month. The industry inventory of row crop tractors were 33% of previous 12 months sales and Deere's inventory of row crop tractors was lower than the industry inventory. Sales of four-wheel drive tractor sales decreased in double digits in May, in stark contrast to the 8% growth witnessed across the industry during the month. Deere's inventory for the four-wheel drive tractor was in line with the industry inventory at 23% of the previous 12 months sales.

Combine sales fared better, pitted against 18% growth in the industry. Deere's inventory for the combines was slightly lower than the industry inventory at 20% of the previous 12 months sales. Retail sales of selected turf and utility equipment were up in double digits. In Europe, retail sales of tractors were up in low double digits, while combine sales went down by double digit. Coming to the Construction and forestry segment, sales went up in single digits.

Compared with the company's performance in April, sales for utility tractor remained the same while row crop tractors fared better. Sales for four-wheel drive contracted by double digits in May as compared with low double-digits decline in April. In Europe, tractor sales were up in low double digits as against single-digit contraction in April. Combine sales con! tracted in double digits versus flat sales in April.

Peer's Performance

Deere's performance was better than that of Caterpillar Inc. (CAT). Sales growth for the construction and mining equipment continued to be in the red with a decline of 7% in May, the sixth consecutive month of decline.

Earnings and Expectations

Deere reported record second quarter 2013 earnings of $2.76 per share, up 6% year over year. Quarterly sales also increased 9% to $10.9 billion. Both were ahead of the respective Zacks Consensus Estimates. The Agriculture & Turf segment sales increased 12% to $8.69 billion, attributable to higher shipment volumes and improved price realization, partially offset by a negative currency translation. Construction & Forestry experienced a 6% year-over-year decline in sales to $1.57 billion, due to lower shipment volumes.

Deere expects equipment sales to grow around 3% in the third quarter of fiscal 2013 and 5% for the full year. Segment-wise, Deere expects worldwide sales of Agriculture and Turf equipment to grow 7% in fiscal 2013. Higher commodity prices and strong farm incomes are expected to boost demand for farm machinery during the year. Furthermore, Deere's sales are expected to benefit from global expansion and new lines of advanced equipment.

Construction & Forestry equipment are expected to decline 5% in 2013, driven by cool, wet weather conditions in North America, flat sales in world forestry markets and reflecting a cautious outlook for the U.S. economic growth. Weakness in the European markets will continue to affect the forestry markets.

Conclusion

Deere will benefit from recovery in construction sector and strength in Brazil. However, continued weakness in the European markets, additional import duty imposed in Russia, Kazakhstan and Belarus, margin headwinds that include higher production costs associated with interim Tier 4 as well as global growth expenses remain concerns.

Deere currently r! etains a ! Zacks Rank #3 (Hold). Other stocks in the same industry that are worth a look include Kubota Corporation (KUB), which retains a Zacks Rank #1 (Strong Buy), and Lindsay Corporation (LNN), which carries a short-term Zacks Rank #2 (Buy).

Sunday, August 25, 2013

GTSO & Partners Plan Major Latin American Expansion (OTCBB:GTSO, OTCMKTS:CLNO)

gtso

Green Technology Solutions, Inc. (GTSO)

Today, GTSO has shed (-5.66%) down -0.0018 at $.0300 with 22,150 shares in play thus far (ref. google finance Delayed: 11:34AM EDT July 3, 2013), but don't let this get you down.

Previously after forging a new joint venture, Green Technology Solutions, Inc. and Chilerecicla are already hard at work identifying new Latin American companies and locales ideally suited to the partnership's ambitious expansion plans.

The partnership has targeted Latin America for expansion because it's a key emerging market in the booming global e-waste recycling and reuse services industry, which Transparency Market Research predicts accounted for more than $9 billion in 2012. The firm expects the worldwide e-waste market to reach $18 billion in 2017, growing at a compound annual growth rate of 13.2 percent from 2012 to 2017.

Green Technology Solutions, Inc. (GTSO) 5 day chart:

gtsochart

clno

Cleantech Transit, Inc. (CLNO)

Cleantech Transit, Inc. (OTCMKTS:CLNO) (www.cleantechtransit.net ) through its Discovery Carbon subsidiary, develops emissions offset strategies for companies, municipalities, and countries. Today, CLNO has shed (-1.60%) down -0.004 at $.246 with  827,051 shares in play thus far (ref. google finance Delayed: 12:39PM EDT July 3, 2013). Earlier that same morning (July 3), this company hit as low as $.20 and as high as $.269. The fact that their is under a million shares in play today thus far and for the last 3 weeks plus their has been over a million shares in play only ignites the exciting potential growth this company might bring to the table along with active savvy investor interest.

FYI – (July 3) Cleantech Transit, Inc. Files DEF 14C http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9386382

Cleantech Transit, Inc. (CLNO ) 5 day chart:

clnochart

Friday, August 23, 2013

Tax Planning Tool Shows Impact on Retirement Plans

MassMutual on Tuesday launched a tool for advisors working with small business owners to help show their clients the way tax changes that take effect this year will impact their retirement plans.

The program, Solutions for Taxing Times, includes a run-down of 2013 taxes and their effect on various income levels and suggested talking points to help simplify conversations with clients. A calculator is also available to estimate potential tax savings and account balance at retirement.

The program also helps advisors identify which of their small-business clients are most likely to need help.

“Tax-advantaged retirement plans can be structured to show small businesses how to contribute a larger percentage of eligible compensation, thus reducing their tax impact while helping them to save more for retirement,” Thomas Foster, national retirement spokesperson for MassMutual’s Retirement Services Division, said in a statement.

Tom Foster, MassMutual“Our driving principle is to allow Americans to retire on their own terms,” Foster (right) told ThinkAdvisor on Thursday. “We approach that by engaging employers and educating employees.”

Foster said MassMutual surveyed advisors across channels to find out what issues are affecting their ability to grow. The survey found taxes, health care and participants’ retirement readiness are the major challenges advisors face.

Foster said advisors wanted guidance on tax planning issues in a “simplified, focused manner. We spend a lot of time on theory, but not a lot on practicality,” he said.

To address advisors’ concerns, Foster said, “we identified certain new taxes and isolated them by adjusted gross income.”

MassMutual then created a “cumulative peak” to show how those taxes would affect various income levels.

Some of those taxes include a 2% increase on Social Security taxes; a 0.9% surtax on Medicare and earned income for people with an adjusted gross income higher than $200,000; changes to allowable personal exemptions and itemized deductions at the $250,000-$300,000 level; and higher capital gains rate for the $400,000-$450,000 level.

MassMutual’s program includes graphs to show the increase, Foster said, then provides an example of how an individual would be affected in 2013 compared to what they paid in 2012.

“It gives them a way to engage with their CPA,” Foster said.

In addition to the online tools, which can be accessed at MassMutual’s website, other tools like postcards are also available. “We found one delivery system isn’t a good way to reach people,” Foster said. “Any tools we offer can be accessed multiple ways.”

Sunday, August 18, 2013

ISRG Reports Prelims for 2Q - Analyst Blog

Hot Financial Stocks To Buy For 2014

Intuitive Surgical (ISRG) has released disappointing preliminary results for the second quarter of 2013. The results were affected by weak sales of the company's da Vinci Surgical Systems. Sales for this flagship product are expected to decline by 6% during the quarter.

Though revenues are expected to grow 7% to $575 million, it lags the Zacks Consensus Estimate of $631 million by roughly 9%. Preliminary second-quarter net income is expected to be $160 million, up 3% year over year. The current Zacks Consensus Estimate for earnings in the second quarter is pegged at $4.32.

Intuitive Surgical, based in Sunnyvale, CA, managed to sell 143 da Vinci Surgical Systems in the second quarter compared with 150 in the year-ago quarter. Sales increased everywhere, including Europe, Japan and the rest of the world, except the U.S.

Sales of the da Vinci product decreased in the U.S. (from 124 to 90 year over year) due to the ongoing economic pressure to reduce hospital costs and the sluggish growth rate in benign gynecologic surgeries. The decision of healthcare insurers to opt for conservative treatments in outpatient settings led to lower hospital admissions.

This, in turn, resulted in moderate benign gynecologic surgeries. However, da Vinci procedures grew 18% in the quarter on the back of strong general surgery procedures.

Further, instruments and accessories revenues are expected to be $265 million, up 18%. Sales were boosted by healthy procedure growth, partially offset by reduction in stocking orders related to a drop in system sales. Service revenues in the second quarter are expected to grow roughly 14% to $95 million.

Following the announcement of the preliminary results, shares of ISRG plunged 11% (or $56.58) after hours to $443.50 on Monday, Jul 8. ISRG will release its full second-quarter results on Jul 18.

Our Take
!
Lower sales of the flagship da Vinci product is a matter of concern. This is reflected in the company's Zacks Rank #4 (Sell). We believe that Intuitive Surgical's products will experience increased pricing pressure due to the stiff capital spending environment in the U.S.

While we choose to avoid ISRG at this point of time, other medical instruments stocks such as Mako Surgical (MAKO), Natus Medical (BABY) and Globus Medical (GMED) are worth considering. All these stocks carry a Zacks Rank #2 (Buy).

Friday, August 16, 2013

Bet on GameStop as it Hits New High - Analyst Blog

Shares of GameStop Corporation (GME) surged to attain a new 52-week high of $43.01 on Jul 5, 2013, before closing at $42.99. Shares of this Zacks Rank #3 (Hold) stock have amassed a year-to-date return of roughly 70.8%.

Based on the current price, this video game and entertainment software retailer is 3.3% above the Zacks Consensus average analyst price target of $41.61. The company currently trades at a forward P/E of 13.81x, in line with the peer group average. Additionally, the company's long-term estimated EPS growth rate is 13.7%.

GameStop is well positioned to take the advantage of the growing market for video game products and PC entertainment software. The company's strategy is to branch out through store expansions in favorable localities by providing the largest title collection of video games and leveraging its first-to-market distribution network to offer the latest hardware and software releases.

GameStop has been evolving continuously and transformed as a mixed retailer of physical and digital gaming and electronic products. The company's ventures in digital, iDevice and gaming tablet businesses are expected to be accretive to its results.

Moreover, shares of GameStop have reacted positively to the announcement made by Microsoft Corporation (MSFT) that Xbox One is enabled to play used games and is not going to levy platform fee, thus enabling the smooth transfer of used and pre-owned games. GameStop's buy-sell-trade model of selling new games and buying back used games and PowerUp Rewards program make it a popular destination for gamers.

Top 10 Performing Companies For 2014

GameStop is not the only company that is anticipated to benefit from this, as the move is likely to auger well for game publishers like Electronic Arts Inc. (EA) as well.

Alongside, shares of Gap Inc. (GPS) reached a new 52-week! high of $43.39 on Jul 5, and eventually closed trade at $43.30.

Thursday, August 15, 2013

Top Medical Stocks To Watch For 2014

Earnings season has begun, and next Tuesday Johnson & Johnson (NYSE: JNJ  ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed, knee-jerk decision.

Johnson & Johnson is a behemoth in the health care space, with a business that includes not only its well-known consumer health and personal-care products, but also a thriving pharmaceutical business and an extensive line of medical devices. The breadth of its offerings has given it a place among the Dow Jones Industrials (DJINDICES: ^DJI  ) . However, with so much going on at J&J, can the company hold itself together and take advantage of new growth opportunities? Let's take an early look at what's been happening with Johnson & Johnson over the past quarter and what we're likely to see in its quarterly report.

Top Medical Stocks To Watch For 2014: Prima BioMed Ltd (PRR)

Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates.

Top Medical Stocks To Watch For 2014: Quintiles Transnational Holdings Inc (Q)

Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company operates in two segments: Product Development and Integrated Healthcare Services. The Company�� Product Development segment operates as a contract research organization (CRO) focused primarily on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company�� Integrated Healthcare Services segment is a global commercial pharmaceutical sales and service organizations and Integrated Healthcare Services provides a range of services, including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as healthcare business services for the healthcare sector, such as outcome-based and payer and provider services. In August 2012, it acquired Expression Analysis, Inc.

Product Development

Product Development provides services and that allow biopharmaceutical companies to outsource the clinical development process from first in man trials to post-launch monitoring. The Company�� service offering provides the support and functional necessary at each stage of development, as well as the systems and analytical capabilities. Product Development consists of clinical solutions and services and consulting. Clinical solutions and services provides services necessary to develop biopharmaceutical products, including project management and clinical monitoring functions for conducting multi-site trials (generally Phase II-IV) (core clinical) and clinical trial support services that improve clinical trial decision making and include global laboratories, data management, biostatistical, safety and pharmacovigilance, and early clinical development trials, and strategic planning and design services that improve decisions and performance. Consulting provides strategy and management consulting services based on life science and advanced analytics, as well as regulatory and comp! liance consulting services.

The Company competes with Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc. (inVentive), INC Research and PRA International.

Integrated Healthcare Services

Integrated Healthcare Services provides the healthcare industry with both geographic presence and commercial capabilities. The Company�� commercialization services are designed to accelerate the commercial of biopharmaceutical and other health-related products. Service offerings include commercial services (sales representatives, strategy, marketing communications and other areas related to commercialization), outcome research (drug therapy analysis, real-world research and evidence-based medicine, including research studies to prove a drug�� value) and payer and provider services comparative and cost-effectiveness research capabilities, clinical management analytics, decision support services, medication adherence and health outcome optimization services, and Web-based systems for measuring quality improvement.

The Company competes with inVentiv, PDI, Inc., Publicis Selling Solutions, United Drug plc, EPS Corporation and CMIC HOLDINGS Co., Ltd.

Hot Undervalued Stocks To Invest In 2014: Telik Inc (TELK.PH)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tole rated. In June 2011, the Company initiated a Phase II clini! c! al trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transf usions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolera bility of the combinations was similar to that expected! of e! ac! h drug ! alone.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60 404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multipl e, standard preclinical models of cancer. TLK6059! 6, a pote! nt! VGFR kin! ase inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

Top Medical Stocks To Watch For 2014: Cannabis Science Inc (CBIS)

Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

Top Medical Stocks To Watch For 2014: StemCells Inc (STEM.W)

StemCells, Inc. (StemCells), incorporated in August 1988, is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�� primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�� human liver cells as a therapeutic product.

CNS Program

The Company in its CNS Program, is in clinical development with its HuCNS-SC cells for a range of disorders of the central nervous system. The CNS includes the brain, spinal cord and eye. In February 2012, the Company had completed a Phase I clinical trial in Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain.

The Company�� CNS Program is focused on developing clinical applications, in which transplanting HuCNS-SC cells protect or restore organ function of the patient before such function is irreversibly damaged or lost due to disease progression. The Company�� initial target indications are PMD, and more generally, diseases in which deficient myelination plays a central role, such as cerebral palsy or multiple sclerosis; spinal cord injury, disorders in which retinal degeneration plays a central role, such as age-related macular degeneration or retinitis pigmentosa. The Company�� product candidate, HuCNS-SC cells, is a purified and expanded composition of normal hum an neural stem cells. Its HuCNS-SC cells can be directly tr! a! nsplanted.

Liver Program

Liver stem or progenitor cells offer an alternative treatment for liver diseases. A liver cellular therapy or cell-based therapeutic provide or support liver function in patients with liver disease. The Company held a portfolio of issued and allowed patents in the liver field, which cover the isolation and use of both hLEC cells and the isolated subset, as well as the composition of the cells themselves.

The Company�� range of cell culture products, which are sold under the SC Proven brand, includes iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2, and NDiff N2B27. Its iSTEM is a serum-free, feeder-free medium that maintains mouse embryonic stem cells in their pluripotent ground state by using selective small molecule inhibitors to block the pathways, which induce differentiation. RHB-A is a defined, serum-free culture medium for the selective culture of human and mouse neural stem cells and their maintenanc e and expansion as adherent cell populations. RHB-Basal is a defined, serum-free basal medium. When supplemented with specific growth factors, this media is formulated for the propagation and differentiation of adherent neural stem cells. RHB-Basal can also be tailored to specific-cell type requirements by the addition of customer preferred supplements.

The Company�� NDiff N2 is a defined serum-free scell culture supplement for the derivation, maintenance, expansion and/or differentiation of human and mouse embryonic stem (ES) cells and tissue-derived neural stem cells supplement. Its NDiff N2-AF is a serum-free and animal component-free version of NDiff N2. Its NDiff N2B27 is a defined, serum-free medium for the differentiation of mouse embryonic stem cells to neural cell types. NDiff N27-AF is a serum-free and animal component-free version of NDiff N27. Its GS1-R is a serum-free media formulation shown to enable the derivation and long-term maintenance of tr ue, germline competent rat embryonic stem cells without! the ! ad! dition ! of cytokines or growth factors. Its GS2-M is a defined, serum- and feeder-free medium for the derivation and long-term maintenance of true, germline competent mouse iPS cells.

The Company also markets a number of antibody reagents for use in cell detection, isolation and characterization. These reagents are also under the SC Proven brand and it includes STEM24, STEM101, STEM121 and STEM123. Its STEM24 is a human antibody that recognizes human CD24, also known as heat stable antigen (HSA), a glycoprotein expressed on the surface of many human cell types, including immature human hematopoietic cells, peripheral blood lymphocytes, erythrocytes and many human carcinomas. Its CD24 is also a marker of human neural differentiation. Its STEM101 is a human-specific mouse antibody that recognizes the Ku80 protein found in human nuclei. Its STEM121 is a human-specific mouse antibody that recognizes a cytoplasmic protein of human cells. Its STEM123 is a human-specific mouse antibody that recognizes human glial fibrillary acidic protein (GFAP).

The Company�� Other products marketed under SC Proven include total cell genomic DNA (gDNA), RNA and protein lysate reagents purified from homogenous stem cell populations for intra-comparative studies, such as Epigenetic fingerprinting, Southern, Western and Northern blots, PCR, RT-PCR and microarrays. This range of purified stem cell line lysates includes mouse embryonic stem (ES) cells propagated in SC Proven 2i inhibitor-based GS2-M media and mouse ES cell-derived and fetal tissue-derived neural stem (NS) cells propagated in SC Proven RHB-A media.

Top Medical Stocks To Watch For 2014: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:
  • [By Victor Mora]

    Elan is a biotechnology company that is looking for ways to improve and better the lives of people with neurodegenerative and autoimmune diseases. The stock has struggled over the last couple of years and looks to be comfortable at these prices. Over the last four quarters, investors in the company have been disappointed as earnings have decreased while revenue figures have increased. Relative to its peers and sector, Elan has been a year-to-date performance leader. WAIT AND SEE what Elan does in coming quarters.

Wednesday, August 14, 2013

February Value Idea Contest Opens; The First $1,000 Award Announcement

GuruFocus' Value Idea Contest is on again. Do you have a favorite stock you know is a good value deal? Submit your analysis of it and post it under "Value Idea Contest." Our judges will select the most thorough, compelling and well-researched value investment idea and present the winner $500.

If an idea doubles within a year, the contestant will win more. This month, GuruFocus is awarding author Jean-Francois Nobert (Ecotycoon) $1,000 for his idea, Research In Motion (RIMM), which doubled since he submitted in July.

Learn more about how GuruFocus judges submissions, or read former contest submissions, in July's winner announcement here.

These are the articles that were submitted in July, to give you an idea of the level of analysis you should aim for:

Time to Buy Research In Motion? RIMM
Supervalu Is a Super Investment Value SVU
Aflac - Value Idea Contest AFL
Applied Materials offers stability within the volatile tech sector AMAT
RIM Success Lies in Paradox RIMM


Qualified authors will also receive $100 per submission. The submissions will be evaluated monthly. The deadline for each month's submissions is the end of the month. Please submit here.

Top 10 Financial Companies For 2014


Related links:RIM Success Lies in ParadoxJuly's winner announcement hereTime to Buy Research In Motion?Supervalu Is a Super Investment ValueAflac - Value Idea ContestApplied Materials offers stability within the volatile tech sectorPlease submit

Saturday, August 10, 2013

Can SanDisk See Higher Prices?

With shares of SanDisk (NASDAQ:SNDK) trading around $58, is SNDK an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let's analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

SanDisk designs, develops, and manufactures data storage solutions in a range of form factors, using its flash memory, controller, and firmware technologies. The company's solutions include removable cards, embedded products, USB, digital media players, wafers and components. Its removable cards are used in a range of consumer electronics devices, such as mobile phones, digital cameras, gaming devices, and laptop computers. SanDisk’s embedded flash products are used in mobile phones, tablets, ultrabooks, eReaders, GPS, gaming systems, imaging devices, and computing platforms. For computing platforms, it provides storage solutions known as solid-state drives that can be used in lieu of hard disk drives. The products that SanDisk provides allows for consumers and companies worldwide to operate at increasing efficiency. These storage products will be in demand at growing rates due to the rising technology expectations of businesses and people around the world.

T = Technicals on the Stock Chart are Strong

SanDisk stock has seen an impressive run since establishing lows during the 2008 Financial Crisis. The stock is currently trading at multi-year highs and looks poised to test all-time highs. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, SanDisk is trading above its rising key averages which signal neutral to bullish price action in the near-term.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

Hot Blue Chip Stocks For 2014

SNDK

(Source: Thinkorswim)

Taking a look at the implied volatility (red) and implied volatility skew levels of SanDisk options may help determine if investors are bullish, neutral, or bearish.

Implied Volatility (IV)

30-Day IV Percentile

90-Day IV Percentile

SanDisk Options

32.79%

66%

65%

What does this mean? This means that investors or traders are buying a significant amount of call and put options contracts, as compared to the last 30 and 90 trading days.

Put IV Skew

Call IV Skew

June Options

Average

Average

July Options

Average

Average

As of today, there is an average demand from call and put buyers or sellers, neutral over the next two months. To summarize, investors are buying a significant amount of call and put option contracts and are leaning neutral over the next two months.

On the next page, let’s take a look at the earnings and revenue growth rates and the conclusion.

E = Earnings Are Increasing Quarter-Over-Quarter

Rising stock prices are often strongly correlated with rising earnings and revenue growth rates. Also, the last four quarterly earnings announcement reactions help gauge investor sentiment on SanDisk’s stock. What do the last four quarterly earnings and revenue growth (Y-O-Y) figures for SanDisk look like and more importantly, how did the markets like these numbers?

2013 Q1

2012 Q4

2012 Q3

2012 Q2

Earnings Growth (Y-O-Y)

47.83%

-23.33%

-67.71%

-95.10%

Revenue Growth (Y-O-Y)

11.21%

-2.25%

-10.09%

-24.93%

Earnings Reaction

-6.64%

2.51%

2.7%

10.31%

SanDisk has seen decreasing earnings and revenue figures over most of the last four quarters. Regardless, the markets seem to have been pleased with most of SanDisk’s recent earnings announcements.

P = Excellent Relative Performance Versus Peers and Sector

How has SanDisk stock done relative to its peers, Intel (NASDAQ:INTC), OCZ Technology (NASDAQ:OCZ), STEC (NASDAQ:STEC), and sector?

SanDisk

Intel

OCZ Technology

STEC

Sector

Year-to-Date Return

33.75%

17.31%

-28.27%

-27.18%

12.45%

SanDisk has been a relative performance leader, year-to-date.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

Conclusion

SanDisk provides data storage products and solutions to consumers and companies at an increasing rate. The stock has been on an impressive run over the last few years and looks to be ready to test previous all-time high prices. Earnings and revenue figures have decreased over most of the last four quarters, which has not really disappointed investors. Relative to its peers and sector, SanDisk has been a year-to-date performance leader. Look for SanDisk to OUTPERFORM.

Thursday, August 8, 2013

No Finance Degree? No Problem! Top 10 Ways To Jumpstart A Career In Finance

A finance or business degree is a prerequisite for most jobs in finance, but what if you don't possess a finance degree and really want to work in this field? While it is obviously more difficult for someone with a non-financial degree to secure a job in finance than it is for a candidate with one, there's still hope for the former.

Every employer wants smart, committed and motivated employees who can do the job and do it well. A finance degree will impart skills such as financial modeling and analysis, but may not do much to provide other skills required for success in almost any job, such as communication, problem-solving and time management.

The following are 10 ways to demonstrate to potential employers that you possess the skills they desire in an employee, as well as the passion necessary for a successful career in finance. We will rate each of these by the degree of difficulty to achieve (for example, signing up for a financial course is easier than obtaining an internship) as well as the positive impact it may have on getting you closer to your objective of embarking on a financial career.

1. Learn the Lingo
Difficulty: Low
Impact: Low

If you are interested in a financial career, there's no excuse for not knowing the lingo of Wall Street. If you don't know the difference between dilution and dividend, or between NPV and DCF, consider learning financial terms and concepts by browsing the extensive dictionary of terms at sites like Investopedia or by reading the Wall Street Journal.

Not knowing the language of finance may make it almost impossible to get past the preliminary interview stage for a non-financial graduate. That's because an interviewer will generally assume that an applicant for a finance position is knowledgeable about finance, regardless of his or her educational background.

2. Round off Your Education
Difficulty: Low to Moderate
Impact: High

So what if you graduated with a degree in a subject other than finance? You can always redress the situation by taking relevant courses with an emphasis on finance or business at the undergraduate or post-graduate level. At the undergraduate level, courses in economics, accounting or financial analysis are a great option. For post-graduates, the favored option for many is an MBA, since the substantial finance component of the curriculum serves to level the playing field quite significantly between finance and non-finance graduates. If the stiff cost of an MBA is a deterrent, other options such as enrolling in the CFA program are certainly worth exploring.

3. Enroll in Financial Boot Camp
Difficulty: Moderate
Impact: Moderate

Intensive courses by firms like Wall Street Prep and Training the Street can teach you valuable skills that are essential for a career in finance, such as advanced spreadsheet techniques and financial modeling. These crash courses are quite expensive, typically running to a few thousand dollars, but have the advantage of not requiring a long-term time commitment, as they are typically conducted over a few days. One drawback is that due to these programs' intensity, you may need to be familiar with basic financial concepts to derive the maximum benefit from them.

4. Expand Your Knowledge Base
Difficulty: Moderate
Impact: High

Relevant knowledge is not obtained only through a college degree. There are plenty of resources available, either through your local library or online, to further your knowledge of finance. These resources may be free or available on a paid basis from course providers such as those mentioned above. Being self-taught in a difficult field like finance demonstrates a number of desirable attributes to an employer such as initiative, passion and drive.

5. Use a Trading Simulator
Difficulty: Moderate
Impact: Low

A number of financial education and online brokerages have trading simulators that can be used to construct "mock" portfolios. Using a trading simulator will force you to track the markets and keep abreast of market developments. This is a great way to impress a potential employer with your trading prowess, or at least your market knowledge, with very little investment on your part, aside from some time commitment.

6. Complete Industry Courses
Difficulty: High
Impact: High

Completing a relevant industry course, such as the Canadian Securities Course™ in Canada, for example, not only demonstrates your commitment to a career in finance, but also gives you an edge on the competition in terms of job readiness. This option may not be available in all jurisdictions; for instance, in order to write the Series 7 exam in the United States, one has to be sponsored by a member firm, a self-regulatory organization or an exchange. In this case, consider the options mentioned in the earlier points.

7. Maintain a Financial Blog
Difficulty: High
Impact: Moderate

Starting and maintaining a financial blog is a great way to communicate your investment ideas to the world. It is an opportunity to convey to a potential employer a favorable impression of your diverse skill set, including financial acumen, communication skills and technological dexterity. This mode of self-marketing is only suitable for those who already possess a measure of these skills.

8. Link up with a Mentor
Difficulty: High
Impact: Moderate

Linking up with a mentor is another way of jumpstarting a financial career. A mentor can be anyone in a position of influence who thinks highly of your capabilities and is willing to help you achieve your goals. Possible mentors include your favorite professor at college, a family friend or relation with a successful career in finance or someone you know in a professional capacity, such as a supervisor during a previous internship. Don't hesitate to approach a contact who you think could help you in your job search.

9. Score a Meaningful Internship
Difficulty: Very High
Impact: Very High

Scoring a summer internship still remains one of the best ways to lock in a prestigious full-time job in finance, as many Wall Street firms pick their new hires from the ranks of their summer interns. At the best business schools, an estimated one-third to half of MBA students work for their summer employer after graduation.

But since obtaining a paid internship in finance is likely to be very difficult for a non-financial graduate, one must consider other options such as an unpaid internship or volunteer work with a broker. The opportunity cost that arises from doing such unpaid internships or volunteer work will be more than offset in due course by the higher earning potential of a finance career.

10. Do Your Best to Get Your Foot in the Door
Difficulty: Very High
Impact: Very High

Knock on doors, expand your job search to other locations, use your network to check for job openings – in short, do everything you can to get your foot in the door of a financial organization. Getting an entry-level position with a financial company, even in a non-finance role, may open doors to other career paths in finance down the line.

The Bottom Line
Some non-finance degrees are certainly in demand on Wall Street for specific tasks, including:
Physics and mathematics for structured products, derivatives and quantitative trading Information technology for algorithmic trading and platform development Engineering, mining and medical for sector-specific research analysis and investment banking But for the vast majority of non-finance degree holders, getting a job in finance is likely to pose a significant challenge. This is more so because thousands of positions were eliminated by banks and financial institutions in the aftermath of the 2008 global recession. However, using a combination of the tips discussed above should enable a non-financial graduate to substantially improve his or her chances of launching a career in finance.

Wednesday, August 7, 2013

Is Google Still a Buy Today?

Returning to its roots as a stalwart growth stock, search giant Google (NASDAQ: GOOG  ) has proven doubters wrong over the last several months by solidly beating the market. Even as one of the largest publicly traded companies in the world, Google remains one of the most attractive businesses around. The trouble for today's investors is that thanks to its impressive run lately, the stock now trades at some pretty lofty multiples. Does that mean investors would be better served looking elsewhere, or does Google have what it takes to keep delivering for long-term investors? Fool contributor Andrew Tonner tackles these questions in the video below.

Its recent run and expanded multiples certainly make it more important than ever to understand each piece of Google's sprawling empire. In The Motley Fool's premium research report on Google, we break down the risks and potential rewards for Google investors. Simply click here now to unlock your copy of this invaluable resource.

#pitch{ margin-bottom: 15px; }
More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

Tuesday, August 6, 2013

Why Polymetal International, Fresnillo, and Eurasian Natural Resources Should Lag the FTSE 100 Today

LONDON -- The FTSE 100 (FTSEINDICES: ^FTSE  ) has seen little change this morning, down 0.15% to 6,713 as of 8:45 a.m. EDT, but it remains close to the its 10-year high of 6,732.4, set in June 2007.

So which companies are holding back the indexes today? Here are three whose share prices are falling and look set to lag the wider market.

Polymetal (LSE: POLY  )
London-listed gold and silver producer Polymetal International is down 4.3%, continuing its fall since the turn of the year, when it was trading for as much as 1,218 pence -- today it stands at 606 pence.

Linked with the price of gold, which has been plummeting recently following the record prices in recent years, the likes of Polymetal are looking to cut costs ahead of further drops in the price of the precious metal.

Fresnillo (LSE: FRES  )
Miners are not in fashion, and especially not gold and silver producers. Fresnillo isn't faring too well, either: Its shares are down 2.7% at the time of writing.

Many of the reasons for Polymetal's underperformance apply also to Fresnillo, which relies on the price of gold faring well. The beginning of the year saw it trade at about 1,810 pence, while it can now be picked up for 1,040 pence.

Eurasian Natural Resources (LSE: ENRC  )  
Completing the set, shares in Eurasian Natural Resources have fallen 2.7% in early trade. This follows the announcement that a rejected consortium bid, announced last week, valued the company at 260 pence (comprising 175 pence in cash and 0.231 of an existing Kazakhmys share for each ENRC share).

The consortium consisted of Kazakhstan's government and ENRC's co-founders, and a successful bid would have cost about $4.8 billion. The consortium now has until June 3 to "either announce a firm intention to make an offer for the Company in accordance with the Code or announce that they do not intend to make an offer."

Finally, reliable dividends can more than compensate for the day-to-day ups and downs of share prices. So how about a company that's offering a 5% yield and could be set for some nice share-price appreciation, too? It's the subject of our brand-new report "The Motley Fool's Top Income Share For 2013," which you can get completely free of charge -- but it will only be available for a limited period, so click here to get your copy today.

Monday, August 5, 2013

Top 5 Cheap Stocks For 2014

Frustrated Apple (NASDAQ: AAPL  ) investors could catch a break next week. The consumer tech giant's annual showcase for developers is coming, and the market just doesn't care.

Apple stock has shed 20% of its value since last year's WWDC, and the carnage is closer to 36% since peaking the day the iPhone 5 hit the market. The shares may be trading 17% higher since bottoming out two months ago, but we're still eyeing a year-to-date slide of 15%.

In short, Apple stock has been a dud. There's no hype heading into Apple's weeklong event, and that's where bulls have the advantage.

No one expects new iPhones (either cheaper or larger versions)�until later this year. The same thing can be said about the iTV chatter, and who knows if that will ever materialize?

Top 5 Cheap Stocks For 2014: SMTC Corporation(SMTX)

SMTC Corporation provides advanced electronics manufacturing services to original equipment manufacturers (OEMs) worldwide. The company?s services include product design and engineering services, printed circuit board assembly production, enclosure fabrication, systems integration, testing, and configuration services. It also provides enclosure and precision metal fabrication, cable assembly, interconnect, and engineering design services. The company offers its integrated contract manufacturing services to OEMs and technology companies primarily in the industrial, computing and networking, communications, consumer, and medical market segments. SMTC Corporation was founded in 1985 and is based in Markham, Canada.

Advisors' Opinion:
  • [By Paul]

    SMTC Corp. (NASDAQ: SMTX) is a Canadian company that provides contract electronics manufacturing services, such as surface-mount and through-hole circuit board assembly, product design, testing, packaging and supply chain management. Manufacturers use products built or assembled by SMTC in their computer servers, networking devices or communications products.

    In its most recent earnings report, the company said Q3 sales rose 48% in the quarter to $65.4 million, and earnings per share were 16 cents, up from 3 cents in the same quarter of 2009. Eight of its top 10 customers increased orders as a result of strong market demand for electronics manufacturing. The addition of five new clients added $10 million to the company’s sales in the quarter. SMTX’s year-over-year gross profit more than doubled to $7.9 million, as a result. Generated cash flow reached $4.6 million and the company used much of this extra cash to pay down debt. That’s why SMTX’s debt was just $18 million at the end of the quarter, the lowest level in the company’s history.

    SMTX is in an excellent position to profit from increasing electronics and technology demand, which will continue to climb next year. Buy SMTX below $4.

Top 5 Cheap Stocks For 2014: Compass Minerals Intl Inc(CMP)

Compass Minerals International, Inc., through its subsidiaries, produces and markets inorganic mineral products primarily in North America and the United Kingdom. The company operates in two segments, Salt and Specialty Fertilizer. The Salt segment produces salt and magnesium chloride for use in road deicing and dust control, food processing, water softeners, pool salt, and agricultural and industrial applications. This segment also purchases potassium chloride and sells as a finished product. The Specialty Fertilizer segment produces and markets sulphate of potash crop nutrients and industrial grade sulfate of potash for use in the production of specialty fertilizers for vegetables, fruits, potatoes, nuts, tobacco, and turf grass. The company also produces and markets consumer deicing and water conditioning products, ingredients used in consumer and commercial food preparation, and other mineral-based products for consumer, agricultural, and industrial applications. In ad dition, Compass Minerals provides records management services to businesses located in the U.K. The company operates rock salt mines in Goderich, Ontario, Canada; and Winsford, Chesire, the United Kingdom. It primarily serves producers of intermediate chemical products used in the production of vinyls and other chemicals, and pulp and paper, as well as water treatment and other industrial uses. The company markets its products through direct sales personnel, contract personnel, and a network of brokers or manufacturers? representatives. Compass Minerals International, Inc., formerly known as Salt Holdings Corporation, was founded in 1993 and is headquartered in Overland Park, Kansas.

Advisors' Opinion:
  • [By Roberto Pedone]

    Compass Minerals (CMP) is a producer of minerals, including salt, sulfate of potash specialty fertilizer and magnesium chloride. This stock closed up 3.4% at $75.60 in Wednesday's trading session.

    Wednesday's Volume: 913,000

    Three-Month Average Volume: 212,481

    Volume % Change: 315%

    From a technical perspective, CMP gapped higher here off its recent low of $64.24 with heavy upside volume. This stock recently gapped down sharply from around $90 to $64.24 with heavy downside volume. That move pushed shares of CMP into extremely oversold territory, since the stock's current relative strength index reading is 25.78. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce higher from. Shares of CMP are now starting to move within range of triggering a near-term breakout trade. That trade will hit if CMP manages to take out its gap down day high of $78.20 and then once it clears its 200-day moving average at $79.14 with high volume.

    Traders should now look for long-biased trades in CMP as long as it's trending above Wednesday's low of $73.07 or $72.50 and then once it sustains a move or close above those breakout levels with volume that's near or above 212,481 shares. If that breakout hits soon, then CMP will set up to re-fill some of its previous gap down zone that started near $90.

  • [By Chris Stuart]

    Compass Minerals International(CMP) is a provider of highway de-icing salt and specialty fertilizer. The salt segment for Compass currently comprises about 80% of the overall business and is stable, yet slow-growing. The specialty potash segment (20% of sales) produces sulfate of potash (SOP), which is used primarily as a specialty fertilizer for vegetables, fruits, tea, tobacco and grass. The SOP business has much better upside and should fuel growth for the company.

    With margins expected to improve in 2011 and management investing to take advantage of improved potash pricing, the stock looks like a solid investment. TheStreet Ratings has a $115 price target on Compass Minerals.

Hot Cheap Stocks To Watch Right Now: DRDGOLD Limited(DROOY)

DRDGOLD Limited engages in the exploration, extraction, processing, and smelting of gold in South Africa. It holds interests in the Blyvoor mine; and the Crown gold surface tailings retreatment facility that reprocesses sand and slimes dumps, as well as involves in the surface retreatment operations. The company was incorporated in 1895 and is based in Roodepoort, South Africa.

Advisors' Opinion:
  • [By seekingalpha.com]

    With mining assets in South Africa, the company runs operations from exploration through to smelting.

    Shares are trading at $4.23 at the time of writing, toward the bottom end of their 52-week trading range of $3.96 to $6.23. At the current market price, the company is capitalized at $162.80 million. Earnings per share for the last fiscal year were $1.21, placing the shares on a price to earnings ratio of 3.49. It paid a dividend of $0.06 last year (a yield of 1.40%) which was covered over 20 times by its earnings.

    It has the lowest price-to-earnings ratio of the gold mining stocks, though its share price is being held back by recent employee unrest in the region. There is room for the company to increase its well-covered dividend, and that should be attractive to income investors. With gold prices increasing, and production costs likely to remain stable, DRDGold could be a stock worth investing in for the gearing that the safe haven value of its gold reserves offers to its potential earnings.

Top 5 Cheap Stocks For 2014: Aegon NV(AEG)

AEGON N.V. provides life insurance, pensions, and asset management products and services worldwide. The company?s life insurance products include traditional, term, universal, whole, and other life insurance products sold as part of defined benefit pension plans, endowment policies, post-retirement annuity products, and group risk products; supplemental health insurance products comprise accidental death, other injury, critical illness, hospital indemnity, medicare supplement, and student health; specialty lines consists of travel, membership, and creditor products; and long term care insurance products for policyholders who require care due to a chronic illness or cognitive impairment. It also offers a range of savings and retirement products and services, including mutual funds, and fixed and variable annuities, savings accounts and investment contracts, segregated funds, guaranteed investment accounts, and single premium immediate annuities, as well as investment advice to individuals. In addition, the company offers employer solutions and pensions, such as retirement plans, pension plans, and pension-related products and services; investment products, including onshore and offshore bonds, and trusts; reinsurance products and solutions to life insurance and financial services companies; general insurance products comprising house, car, and fire insurance; and asset management products and services, including general account assets, unit-linked funds, and third party activities. AEGON N.V. markets its products through independent and career agents, financial planners, registered representatives, independent marketing organizations, banks, broker-dealers, benefit consulting firms, wirehouses, affinity groups, institutional partners, independent managing general agencies, and specialized financial advisors, as well as through online, direct, and worksite marketing. The company was founded in 1900 and is headquartered in The Hague, the Netherl ands.

Advisors' Opinion:
  • [By seekingalpha.com]

    Shares of this life insurance company are trading at $4.25 at the time of writing, and at the low end of their 52-week trading range of $4.18 to $8.07. At the current market price, the company is capitalized at $7.50 billion. Earnings per share for the last fiscal year were $0.69, placing the shares on a price-to-earnings ratio of 6.13.

    These earnings are expected to rise through the next couple of years, hitting $0.73 this year, and then rising to $0.89 the following year. AEG received Dutch government aid in the 2008 financial crisis, and has been selling operations to repay its debts. The latest sale, Guardian Life in the U.K. for $451 million, takes it a step closer to achieving this goal. It will continue to manage Guardian’s assets of £7.5 billion (approximately $11 billion).

    Well on the way to achieving its target of full repayment to the Dutch government, and continuing to shed non core assets, for Aegon it is deals like the Guardian one that will push it to a better-managed profit stream. When the company has fully repaid its debts, it is likely to reinstate dividend payments. This will help the stock price near and long term.

Top 5 Cheap Stocks For 2014: WebMediaBrands Inc(WEBM)

WebMediaBrands Inc., an Internet media company, provides content, education, and career services to media and creative professionals through a portfolio of vertical online properties, communities, and trade shows. The company operates mediabistro.com, a blog network that provides content, education, community, and career resources about media industry verticals, including new media, social media, Facebook, TV news, sports news, advertising, public relations, publishing, design, mobile, and the semantic Web. Its mediabistro.com also includes a job board for media and business professionals focusing on various job categories, such as social media, online/new media, publishing, public relations/marketing, advertising, sales, design, and television. The company also operates a network of online properties, including AdsoftheWorld, DynamicGraphics, LiquidTreat, BrandsoftheWorld, Graphics.com, StepInsideDesign, Creativebits, and GraphicsDesignForum that provide content, educatio n, community, career, and other resources for creative and design professionals. In addition, it offers community, membership, and e-commerce offerings comprising a freelance listing service, a marketplace for designing and purchasing logos, and premium membership services. Further, the company provides online and in-person courses, panels, certificate programs, and video subscription libraries for media and creative professionals. Additionally, it organizes various trade shows that include Semantic Technology Conference, Monetizing Social Media, Social Media Optimization Conference, Social Gaming Summit, and Virtual Goods Summit. The company was formerly known as Jupitermedia Corporation and changed its name to WebMediaBrands Inc. in February 2009. WebMediaBrands Inc. was founded in 1999 and is based in New York, New York.

Sunday, August 4, 2013

Top Cheap Stocks To Watch For 2014

Once the most valuable company in the world, Apple (NASDAQ: AAPL  ) stock dipped below $400 this week to bottom out at its lowest levels since 2011. Yet as shares of Apple continue to free-fall, the stock's valuation becomes increasingly more attractive. The stock is currently trading at just nine times earnings, well below the market average of 15 times earnings.

From a valuation standpoint, this means Apple stock is trading at its cheapest level in at least 10 years, according to The Wall Street Journal.

Why you want to own it
The stock looks even better when you consider Apple's balance sheet, which boasts zero debt and more than $137 billion in cash and investments. And we can't forget the stock's 2.6% dividend yield. Better still, the company's massive cash reserves mean there's plenty of room for dividend increases or stock buybacks in Apple's future.

Top Cheap Stocks To Watch For 2014: DRDGOLD Limited(DROOY)

DRDGOLD Limited engages in the exploration, extraction, processing, and smelting of gold in South Africa. It holds interests in the Blyvoor mine; and the Crown gold surface tailings retreatment facility that reprocesses sand and slimes dumps, as well as involves in the surface retreatment operations. The company was incorporated in 1895 and is based in Roodepoort, South Africa.

Advisors' Opinion:
  • [By seekingalpha.com]

    With mining assets in South Africa, the company runs operations from exploration through to smelting.

    Shares are trading at $4.23 at the time of writing, toward the bottom end of their 52-week trading range of $3.96 to $6.23. At the current market price, the company is capitalized at $162.80 million. Earnings per share for the last fiscal year were $1.21, placing the shares on a price to earnings ratio of 3.49. It paid a dividend of $0.06 last year (a yield of 1.40%) which was covered over 20 times by its earnings.

    It has the lowest price-to-earnings ratio of the gold mining stocks, though its share price is being held back by recent employee unrest in the region. There is room for the company to increase its well-covered dividend, and that should be attractive to income investors. With gold prices increasing, and production costs likely to remain stable, DRDGold could be a stock worth investing in for the gearing that the safe haven value of its gold reserves offers to its potential earnings.

Top Cheap Stocks To Watch For 2014: Majesco Entertainment Company(COOL)

Majesco Entertainment Company develops and markets video game products primarily for family oriented mass-market consumers. The company publishes video games for various interactive entertainment hardware platforms, including Nintendo?s DS, DSi, and Wii; Sony?s PlayStation 3 and PlayStation Portable; Microsoft?s Xbox 360; and personal computers. It also publishes games for various digital platforms consisting of mobile platforms comprising iPhone, iPad, and iPod Touch, as well as online platforms, including Facebook. The company sells its products primarily to retail chains, specialty retail stores, video game rental outlets, and distributors. The company was founded in 1998 and is based in Edison, New Jersey.

Advisors' Opinion:
  • [By McWillams]

    Majesco Entertainment makes video games mainly for the family-oriented, mass-market consumer.

    Majesco's incredible run this year started on Jan. 11 when the company announced it had shipped more than 500,000 copies of its Zumba Fitness video game title for the Wii, Xbox 360 and PlayStation 3. In late January, the company announced that it regained compliance with the Nasdaq's minimum bid price requirement for continued listing.

    In early March, shares of Majesco climbed higher after the company posted better-than-expected fiscal first-quarter financial results, with revenue jumping to $48.5 million from $29.2 million in the same period a year earlier.

    Current Share Price: $3.20 (March 29)

    First Quarter Total Return: 315%

    Analyst Ratings: Majesco garners a lone "buy" rating from Needham & Co. and a "neutral" rating from Wedbush. Coincidentally, both research firms have a $2.50 price target on the stock.

    TheStreet Ratings has a "hold" recommendation on Majesco Entertainment. The research report from March 20 says revenue growth, a largely solid financial position with reasonable debt levels and solid stock price performance are strengths that are countered by the company's weak cash flow from its operations.

  • [By Louis]

    Majesco Entertainment (NASDAQ: COOL) is an innovative provider of video games for the mass market, developing a wide range of titles for Sony’s PlayStation, Microsoft’s Xbox and Nintendo’s WII systems. On June 7, COOL announced that it had signed a contract with the NBA to begin development of an original video-game basketball franchise. The stock rose an impressive 32% over the next five trading days while the broader market sold off.

    However, the stock is down today after reporting weaker-than-expected second-quarter earnings last night, missing consensus earnings estimates by 2 cents. Majesco reported net revenues of $32.1 million for the second quarter ended April 30, 2011, compared with $10.9 million reported for the same period in the previous year. The company’s operating income for the second quarter was $5.3 million, compared with an operating loss of $1.6 million reported for the same period in the previous year. So treat this sell-off as a buying opportunity.

Top 5 Penny Stocks To Watch Right Now: Lattice Semiconductor Corporation(LSCC)

Lattice Semiconductor Corporation designs, develops, manufactures, and markets programmable logic products and related software. The company offers field programmable gate array (FPGA) products, including LatticeECP family for deployment in wireless infrastructure and wireline access equipment, as well as in video and imaging applications; and LatticeXP for the security, surveillance, and display markets. It also provides programmable logic device (PLD) products comprising various versions of ispMACH4000 in-system programmable complex programmable logic device family; MachXO family that is designed for a range of low density applications; platform manager, power manager, and ispClock programmable mixed signal devices; and software development tools and intellectual property cores. The company sells its products directly to end customers through a network of independent manufacturers? representatives and indirectly through a network of independent sell-in and sell-through distributors. It primarily serves original equipment manufacturers in the communications, computing, consumer, industrial, military, automotive, and medical end markets. The company was founded in 1983 and is headquartered in Hillsboro, Oregon.

Advisors' Opinion:
  • [By Nancy Zambell]

    A survivor of the tech boom and bust cycle, Lattice Semiconductor Corp. (NASDAQ: LSCC) has managed to consistently grow its new product revenue by 28% per quarter since 2006. And that astounding figure includes one of the worst recessions in our history, as well as a downturn in the semiconductor market. The company’s primary customers are original equipment manufacturers (OEMs) in the communications, computing, consumer, industrial, automotive, medical and military end markets. Its strongest markets include the fastest-growing segments in our economy today.

    LSCC intends to focus on aggressively expanding its mid-range markets, as well as its products for lower-power, lower-cost applications. It also plans to continue targeting customized solutions for its customers, all the while, continuing to increase its flow of new product growth and entry into new markets.

Top Cheap Stocks To Watch For 2014: Oracle Corporation(ORCL)

Oracle Corporation, an enterprise software company, develops, manufactures, markets, distributes, and services database and middleware software, applications software, and hardware systems worldwide. It licenses of database and middleware software, including database management software, application server software, service-oriented architecture and business process management software, data integration software, business intelligence software, identity and access management software, content management software, portals and user interaction software, development tools, and Java; and applications software comprising enterprise resource planning, customer relationship management, enterprise performance management, supply chain management, business intelligence applications, enterprise portfolio project management, Web commerce, and industry-specific applications software. The company also offers customers with rights to unspecified software product upgrades and maintenance releases; Internet access to technical content; and Internet and telephone access to technical support personnel. In addition, its hardware systems products consist of computer server and hardware-related software, including the Oracle Solaris Operating System; and storage products, such as tape, disk and networking solutions for open systems and mainframe server environments. Its hardware systems support solutions include software updates for the software components. Further, the company offers consulting solutions in business and IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancements and upgrades; cloud services, including Oracle Cloud Services and Advanced Customer Services; and education solutions comprising instructor-led, media-based, and Internet-based training in the use of its software and hardware products. The company was founded in 1977 and is headquartered in Redwood Ci ty, California.

Advisors' Opinion:
  • [By Bill]  

    Larry Ellison has created a winner in Oracle. This stock has great numbers, cash on hand, and upbeat expectations. All the above are things I like.

Top Cheap Stocks To Watch For 2014: Rent-A-Center Inc.(RCII)

Rent-A-Center, Inc., together with its subsidiaries, primarily engages in leasing household durable goods to customers on a rent-to-own basis. The company?s stores offer durable products, such as consumer electronics, appliances, computers, and furniture and accessories under flexible rental purchase agreements that allow the customer to obtain ownership of the merchandise at the conclusion of an agreed upon rental period. It also provides merchandise on an installment sales basis in its stores. As of December 31, 2010, the company operated 3,008 company-owned stores in the United States, and in Canada, Puerto Rico, and Mexico, including 42 retail installment sales stores under the names ?Get It Now? and ?Home Choice?; and 18 rent-to-own stores located in Canada under the ?Rent-A-Centre? name. It also operates 209 franchised rent-to-own stores in 32 states under the ColorTyme trade name; and 384 kiosk locations under the ?RAC Acceptance? model. In addition, the company, th rough its ColorTyme?s franchised stores, offers custom rims and tires for sale or rental under the trade names ?RimTyme? or ?ColorTyme Custom Wheels?. Rent-A-Center, Inc. was founded in 1986 and is headquartered in Plano, Texas.

Advisors' Opinion:
  • [By Chris Stuart]

    Rent-A-Center(RCII), the largest rent-to-own operator in the U.S., rents furniture and electronics to low- to middle-income customers.

    The company has struggled in the past three months, underperforming its closest competitor, Aaron's Rents(AAN), by over 25%. While Aaron's has executed flawlessly, Rent-A-Center has not, as the company missed earnings estimates. Management blamed the first-quarter fallout on poor weather conditions in February and limited availability of refund-anticipation loans for consumers. Despite the hiccup, management has stuck to its 2011 guidance of $2.90 to $3.10 in EPS, equating to revenue growth of 5% to 7% and earnings-per-share growth of 3% to 10%.

    Key initiatives to boost growth, such as RAC Acceptance (kiosks in third-party stores that arrange rent-to-own programs) are in place. Management has done a good job of managing its debt position and recently boosted the dividend by 167% (now at a 2.2% yield). If management can achieve $3 in EPS for the full year, the stock looks cheap, trading at just 9.7 times earnings (a discount to 15 times P/E for Aaron's). TheStreet Ratings has a $41 price target on shares of Rent-A-Center.

Top Cheap Stocks To Watch For 2014: Aegon NV(AEG)

AEGON N.V. provides life insurance, pensions, and asset management products and services worldwide. The company?s life insurance products include traditional, term, universal, whole, and other life insurance products sold as part of defined benefit pension plans, endowment policies, post-retirement annuity products, and group risk products; supplemental health insurance products comprise accidental death, other injury, critical illness, hospital indemnity, medicare supplement, and student health; specialty lines consists of travel, membership, and creditor products; and long term care insurance products for policyholders who require care due to a chronic illness or cognitive impairment. It also offers a range of savings and retirement products and services, including mutual funds, and fixed and variable annuities, savings accounts and investment contracts, segregated funds, guaranteed investment accounts, and single premium immediate annuities, as well as investment advice to individuals. In addition, the company offers employer solutions and pensions, such as retirement plans, pension plans, and pension-related products and services; investment products, including onshore and offshore bonds, and trusts; reinsurance products and solutions to life insurance and financial services companies; general insurance products comprising house, car, and fire insurance; and asset management products and services, including general account assets, unit-linked funds, and third party activities. AEGON N.V. markets its products through independent and career agents, financial planners, registered representatives, independent marketing organizations, banks, broker-dealers, benefit consulting firms, wirehouses, affinity groups, institutional partners, independent managing general agencies, and specialized financial advisors, as well as through online, direct, and worksite marketing. The company was founded in 1900 and is headquartered in The Hague, the Netherl ands.

Advisors' Opinion:
  • [By seekingalpha.com]

    Shares of this life insurance company are trading at $4.25 at the time of writing, and at the low end of their 52-week trading range of $4.18 to $8.07. At the current market price, the company is capitalized at $7.50 billion. Earnings per share for the last fiscal year were $0.69, placing the shares on a price-to-earnings ratio of 6.13.

    These earnings are expected to rise through the next couple of years, hitting $0.73 this year, and then rising to $0.89 the following year. AEG received Dutch government aid in the 2008 financial crisis, and has been selling operations to repay its debts. The latest sale, Guardian Life in the U.K. for $451 million, takes it a step closer to achieving this goal. It will continue to manage Guardian’s assets of £7.5 billion (approximately $11 billion).

    Well on the way to achieving its target of full repayment to the Dutch government, and continuing to shed non core assets, for Aegon it is deals like the Guardian one that will push it to a better-managed profit stream. When the company has fully repaid its debts, it is likely to reinstate dividend payments. This will help the stock price near and long term.